All Episodes

417: Hospitals' next lucrative bet — longevity clinics

416: NIH funding uncertainty thwarts U.S. researchers

415: Mistrust in science and a juicy gene-editing lawsuit

The FDA's Overton era, and dispatches from Shanghai

Definium's new psychedelics data, and a reprieve for international scientists

Why two promising heart drugs flopped and what's next

411: Capricor's data clash and a fugitive in the C-suite

410: A father’s mission to save his daughter, and allegations on telehealth GLP-1 prescribing

409: Predicting biotech clinical trials & a new Alzheimer's drug controversy

408: Whistleblower takes on health insurance and FDA commissioner candidates

407: The mysterious case of Eli Lilly's obesity drug

406: New hope in treating Huntington's disease and a report card on RFK Jr.'s promises

405: An obesity drug deep-dive, and peptides move mainstream

404: What RevMed's pancreatic cancer drug meant for one patient

403: Biotech exec Jeremy Levin on the industry's strategic turning point

402: Guarding biotech from China and big bets in longevity

401: Makary’s departure and Cassidy’s tenuous Senate seat

400: Seaport's IPO adventure, obesity pill battles, and Makary's troubles

399: Hair-raising trial results, and Servier’s M&A wishlist

398: A CAR-T biotech's dramatic turnaround, and drugmakers' tactics to drive more scripts

397: A pancreatic cancer breakthrough, and new hope for an off-the-shelf CAR-T treatment

396: A new trick for old science, and biotech VCs' scrambled playbook

395: Biotech investors' plea to Trump, and a busy M&A week

394: Eli Lilly's deal man, Allogene's off-the-shelf CAR-T, and Merck's Terns buy

393: A conversation with the 'godfather' of biotech

392: Epstein's pal attempts a biotech comeback, and Prasad exits the FDA

391: Breaching the IBD efficacy ceiling, and sham surgeries

390: FDA turmoil, election intrigue, AI, and more

389: Hims' Super Bowl fallout, and the FDA reverses course

388: The FDA's refusal to review Moderna's mRNA flu vaccine

387: Challenges for a crucial sickle cell treatment and the latest outlook for GLP-1s

From Drug Story: Lipitor and Heart Disease

386: The high stakes for Huntington's patients

385: A measles outbreak and hospitals' financial troubles

384: Live from the JP Morgan conference, a sit-down with Novo Nordisk's CEO and VC Bob Nelsen

383: JPM to bring more deals and happy CEOs

382: Biotech's year in review

381: The future of American science and a dispatch from ASH

380: A new top drug regulator and the future of psychedelics

379: How Mark Cuban plans to ‘f— up’ health care

378: Merck's heart disease win and the FDA's new drug regulator

377: Melodrama at the FDA and the Pfizer-Novo bidding war

376: BridgeBio’s great week and Moderna’s unraveling

375: Startups push the FDA and biotech booms in North Carolina

374: Veteran biotech executive Clive Meanwell on drug pricing and the obesity market

373: Party in biotech land and AstraZeneca’s miscalculation

372: A pharma C-suite shakeup and Trump's deal with Pfizer

371: A gene therapy success in Huntington's and Trump's autism announcement

370: Pharma sours on the U.K., plus biotech M&A's quiet roll

369: Trump, Chinese biotech, and an industry career reshaped by illness

368: New stakes in the vaccine dispute and a boost for biotech

367: The ouster of CDC's director, biotech venture firm rankings

366: Viking’s obesity flop, ‘pharma to table’ drug sales

365: Vinay Prasad’s return, animal testing alternatives, and mRNA upended

364: Closing a zombie biotech, and Lilly's disappointing obesity readout

363: What Vinay Prasad’s ouster means for biotech and the FDA

362: A mother’s perspective on Sarepta’s gene therapy halt

361: Inside an FDA drug rejection, and layoffs at Sarepta

360: NIH grant cuts, FDA transparency questions and biotech M&A

359: Vaccine policy frays, CDC nominee in the hot seat, & obesity drug side effects

358: FDA's gene therapy turmoil, and an alternative model for funding research

357: The upheaval of CDC's vaccine panel, and drug pricing confusion

356: An AI experiment at the FDA & Novo trailing in the obesity drug race

355: Moderna’s vaccine hit, the MAHA report, and an ASCO preview

354: Uncertainty in CRISPR world and the start of more M&A

353: Trump's drug-pricing plan and a potential Theranos 2.0

352: A firebrand takes oversight of vaccines, gene therapies

351: It's gonna be May (in biotech)

350: Pharma tariffs, and a 'sunshine day' for biotech stocks

349: BIO's John Crowley on RFK Jr. and tariffs, plus calls for more federal biotech funding

348: Cuts, ousters and drama at the FDA

347: More HHS upheaval, 23andMe's bankruptcy, and AI for cancer survival

346: Zealand's obesity strategy and Immunovant's curious development plan

345: The sudden withdrawal of a CDC nominee and what went wrong with Covid policies

344: Trump's FDA commissioner nominee takes the hot seat

343: Turbulence at the FDA, Bluebird Bio's sale and young biotech VCs

342: FDA cuts, zombie biotechs, and too much weight loss?

341: NIH funding cuts, a U.S. brain drain, and bold claims from AI drug developers

340: Crisis in CRISPR world, RFK Jr.'s promises, and a novel non-opioid pain drug

339: RFK Jr.'s confirmation hearings, MASH drugs, and a controversial obesity ad

338: Chinese biotechs, a WHO departure, and post-JPM thoughts

337: Eli Lilly CEO on Trump, obesity drugs, and a guidance miss

336: Pharma's big patent cliff, more obesity fundraising, and a failed ALS study

335: A deep dive on Makary, Vertex's pain data, & 2025 predictions

334: Pharma silence on RFK Jr. & parents trying to develop gene therapies for their children

333: An H5N1 bird flu update and talent scarcity in the radiopharma field

332: Pfizer's new R&D head, a VC deep-dive, and a new FDA commissioner?

331: AbbVie’s stumble, Amgen’s tumble and more election fallout

330: How a Trump presidency could affect the FDA, the biotech industry, and its stocks

329: Lilly's earnings surprise, investors mull the election, & a spooky ghost story

328: Pfizer's activist troubles, gene therapy questions, RFK Jr.'s MAHA ambitions

327: Biotech's next gold rush, GLP-1 shortages, and STAT Summit highlights

326: Crypto for CRISPR, a new RNAi startup, & a Nobel for AI

325: Biden's health care AI czar, a new obesity company, and its dealmaking CEO

From Tradeoffs: Race to the Bottom

324: Genentech's cancer pivot, Pfizer's sickle cell withdrawal, and a new schizophrenia drug

323: Cannabinoids for weight loss, a cancelled ad comm, and the Fed lowers interest rates

322: A new threat to Merck's blockbuster cancer treatment, Moderna's cutbacks, and obesity drugs for kids

321: Summit's upcoming cancer results, Recursion's mixed data, and the next big obesity target

320: Jim Wilson's next venture, a surprise startup shutdown, & Lilly's Zepbound strategy